PACB Pacific Biosciences of California Inc.

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025

MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time.

The call will be webcast and may be accessed at PacBio’s website at .

Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)

Listen live via internet or replay: Toll-free: 1-888-349-0136

International: 1-412-317-0459

If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q3 Earnings Call.”

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:

Jim Gibson

Media:



EN
22/10/2025

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces the Appointment of Chris Gibson to the Board of Direc...

PacBio Announces the Appointment of Chris Gibson to the Board of Directors Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a clinical-stage biot...

3h / 53m 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Da...

PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research Collaboration powers secure international data sharing through the HiFi Solves Global Consortium MENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced a collaboration with DNAstack to power the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collaboration enables secure international research — allowi...

February 24, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio to Participate in the TD Cowen 46th Annual Health Care Conferen...

PacBio to Participate in the TD Cowen 46th Annual Health Care Conference  MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026, at 2:30 PM ET in Boston, MA. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event. ...

February 18, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Fourth Quarter and Full Year 2025 Financial Results

PacBio Announces Fourth Quarter and Full Year 2025 Financial Results MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results:  Q4 2025Q4 2024FY 2025FY 2024Revenue (in millions)$44.6$39.2$160.0$154.0Consumable revenue (in millions)$21.6$18.8$82.0$70.3Instrument revenue (in millions)$17.3$15.3$53.8$65.8Service and other revenue (in millions)$5.7$5.1$24.2$17.9RevioTM system placements21236197VegaTM system placements4271407Annualized Revio pul...

February 12, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Pa...

PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease Network MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare disease genomics program of Genetic Alliance, to integrate PacBio’s HiFi® long-read whole-genome sequencing into iHope’s international network. iHope operates the world’s largest eq...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch